Merck has applied to the FDA for emergency approval of the oral antiviral drug molnupiravir for the treatment of mild to moderate coronavirus in adults. Earlier results from a Phase 3 clinical trial showed that the drug reduced the likelihood of hospitalization for patients with Covid-19 by about 50%.